Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Guichard

Showing results (31-40 of 32) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 32 results.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|March 9, 2022
Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancerJ Trédaniel, F Barlési, C Le Péchoux, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 14, 2017
[Spinal stereotactic body radiotherapy: French assessment in 2016]I Pougnet, E Jaegle, R Garcia, et al.
Pageof 4

Showing results (31-40 of 32) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 32 results.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|March 9, 2022
Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancerJ Trédaniel, F Barlési, C Le Péchoux, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 14, 2017
[Spinal stereotactic body radiotherapy: French assessment in 2016]I Pougnet, E Jaegle, R Garcia, et al.
Pageof 4